Dr. Manojkumar Bupathi, MD

Dr. Bupathi practices at Rocky Mountain Cancer Centers in Littleton, Colorado.

Dr. Bupathi's NPI, 1265675433, was assigned on April 17, 2009. Dr. Bupathi holds Colorado license DR.0057961.

Dr. Bupathi's primary practice is Rocky Mountain Cancer Centers, at 22 W Dry Creek Cir, Littleton, CO 80120 in Arapahoe County. The practice phone is (303) 930-7800.

Dr. Bupathi's primary practice is Rocky Mountain Cancer Centers in Littleton, Colorado. Dr. Bupathi is also affiliated with AdventHealth Littleton. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Bupathi to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bupathi practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bupathi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bupathi is licensed in Colorado.

CMS data shows 91,054 Medicare services from Dr. Bupathi across 74 procedure codes in 2024, for 895 Medicare patients. Medicare paid $2,131,954 for them.

CMS counts 895 Medicare patients who saw Dr. Bupathi in 2024. The largest group is 65 to 74, with 421 patients. 75% of them have cancer, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bupathi's median patient age at 71, with 63% women.

In 2024, Dr. Bupathi wrote 4,509 Medicare Part D claims for 669 patients. 81% of them were for generic drugs. CMS names the drug for 4,171 of them, across 67 drugs with 11 or more claims each, at $6,988,290 in total drug cost. In 2023, CMS named 3,581 claims across 60 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Bupathi for performance year 2024, reported through an alternative payment model (APM). Dr. Bupathi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bupathi as offering telehealth.

Dmand AI links 24 papers to Dr. Bupathi, published from 2014 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Antibodies, Monoclonal, Humanized, Camptothecin and Carcinoma, Transitional Cell. Dr. Bupathi has published most often in J Clin Oncol. Dr. Bupathi's most frequent co-authors are Petros Grivas, MD, Arjun Vasant Balar, MD and Phillip Lee Palmbos, MD.

Dmand AI links Dr. Bupathi to 8 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Endometrial Neoplasms, Carcinoma, Endometrioid and Carcinoma, Ovarian Epithelial. Open Payments lists research payments to Dr. Bupathi that name 1 trial.

CMS Open Payments shows 421 general payments to Dr. Bupathi from 36 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Exelixis Inc. paid the most, $71,990. It also lists 4 research payments totaling $6,445 from 2017 to 2018, naming 1 clinical trial.